Preferred Label : CD80-Fc Fusion Protein FPT155;
NCIt related terms : FPT-155;
NCIt definition : A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80
(B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory,
immune checkpoint inhibitory and antineoplastic activities. Upon administration of
CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in
the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation
of T-cell responses including the activation of naïve and memory T-cells. This leads
to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby
killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4;
CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28
engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80
is a co-stimulatory molecule expressed on activated antigen presenting cells that
plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other
hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting
T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily
(IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation.
It plays a key role in the downregulation of the immune system.;
UNII : WK58XJB6UK;
CAS number : 2337381-31-2;
Molecule name : FPT-155; FPT 155;
NCI Metathesaurus CUI : CL1378876;
Origin ID : C169063;
UMLS CUI : C5239579;
Semantic type(s)
- concept_is_in_subset
